Systematic review and meta-analysis demonstrate that Chaihu Guizhi-tang improves depressive symptoms in adults, suggesting its potential in treatment.
Objective: This study assessed the effectiveness and safety of Chaihu Guizhi-tang (CGT) for depressive symptoms through a systematic review and meta-analysis of randomized controlled trials (RCTs).Methods: A search was conducted using keywords such as “Chaihu Guizhi,” “depression,” and “post-stroke depression.” A meta-analysis was performed according to outcome measurements including the Hamilton Depression Rating Scale (HAMD), Total Effective Rate (TER), Hamilton Anxiety Rating Scale (HAMA), Pittsburgh Sleep Quality Index (PSQI), serum 5-hydroxytryptamine (5-HT) levels, and incidence of adverse events, using Review Manager software.Results: Seven RCTs were included. The CGT plus antidepressant group showed significant improvements in HAMD (SMD=-1.10, 95% CI: -1.64 to -0.55, P<0.0001) and TER (RR=1.22, 95% CI: 1.13 to 1.32, P<0.00001), with additional benefits in HAMA, PSQI, and 5-HT levels. The incidence of adverse events was significantly lower in the experimental group than in the control group.Conclusion: Chaihu Guizhi-tang combined with antidepressants may improve depressive symptoms and reduce adverse reactions.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: